Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Sunshine Biopharma (SBFM) over the last 16 years, with Dec 2024 value amounting to $9.3 million.

  • Sunshine Biopharma's Cash from Financing Activities fell 96.13% to $75,536 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 17.86%. This contributed to the annual value of $9.3 million for FY2024, which is 171.18% up from last year.
  • Sunshine Biopharma's Cash from Financing Activities amounted to $9.3 million in FY2024, which was up 171.18% from $3.4 million recorded in FY2023.
  • Sunshine Biopharma's 5-year Cash from Financing Activities high stood at $39.5 million for FY2022, and its period low was $1.6 million during FY2020.
  • Moreover, its 3-year median value for Cash from Financing Activities was $9.3 million (2024), whereas its average is $17.4 million.
  • Per our database at Business Quant, Sunshine Biopharma's Cash from Financing Activities soared by 1,258.68% in 2022 and then crashed by 91.32% in 2023.
  • Over the past 5 years, Sunshine Biopharma's Cash from Financing Activities (Yearly) stood at $1.6 million in 2020, then soared by 80.61% to $2.9 million in 2021, then surged by 1,258.68% to $39.5 million in 2022, then crashed by 91.32% to $3.4 million in 2023, then spiked by 171.18% to $9.3 million in 2024.